Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs

American Journal of Respiratory and Critical Care Medicine

Volumn 154, Issue 5, 1996, Pages 1347-1350

  Naeije, Robert ^a   Maggiorini, Marco ^a   Delcroix, Marion ^a   Leeman, Marc ^a   Mélot, Christina ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; HEART OUTPUT; HYPEROXIA; HYPOXIA; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0029842152     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.154.5.8912746     Document Type: Article

References (30)

1. Rubin, L. J. 1993. ACCP consensus statement. Primary pulmonary hypertension. Chest 104:236-250.
2. Voelkel, N. F., and E. K. Weir. 1989. Etiologic mechanisms in primary pulmonary hypertension. In E. K. Weir and J. T. Reeves, editors. Pulmonary Vascular Physiology and Pathophysiology. Lung Biology in Health and Disease. Marcel Dekker, New York. 38:513-539.
3. Gurtner, H. P. 1990. Aminorex pulmonary hypertension. In A. P. Fishman, editor. The Pulmonary Circulation, Normal and Abnormal. University of Pennsylvania Press, Philadelphia. 29:398-411.2
4. Brenot, F., P. Herve, P. Petitpretz, F. Parent, P. Duroux, and G. Simonneau. 1993. Primary pulmonary hypertension and fenfluramine use. Br. Heart J. 70:537-541.
5. Naeije, R, P. Wauthy, M. Maggiorini, M. Leeman, and M. Delcroix. 1995. Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. Am. J. Respir. Crit. Care Med. 151:692-697.
6. Naeije, R., P. Lejeune, M. Leeman, C. Mélot, and T. Deloof. 1987. Pulmonary arterial pressure/flow plots in dogs. Effects of isoflurane and nitroprusside. J. Appl. Physiol. 63:969-977.
7. Anonymous. Dexfenfluramine. 1991. Lancet 337:1315-1316.
8. McTavish, D., and R. C. Heel. 1992. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 43:713-733.
9. Caccia, S., M. Ballabio, G. Guiso, M. Rocchetti, and S. Garattini. 1982. Species differences in the kinetics and metabolism of fenfluramine isomers. Arch. Int. Pharmacodyn. 258:15-28.
10. Winer, B. J. 1971. Statistical Principles in Experimental Design, 2nd ed. McGraw-Hill, New York. 514-603.
11. Atanassoff, P. G., B. M. Weiss, B. R. Schmid, and M. Tornic. 1992. Pulmonary hypertension and dexfenfluramine (letter). Lancet i:436.
12. Roche, N., S. Labrune, J. M. Braun, and G. J. Huchon. 1992. Pulmonary hypertension and dexfenfluramine (letter). Lancet i:436-437.
13. Douglas, J. G., J. F. Munro, A. H. Kitchin, A. L. Muir, and A. T. Proudfoot. 1981. Pulmonary hypertension and fenfluramine. B.M.J. 283:881-883.
14. Gaul, G., G. Blazek, E. Deutsch, and H. Heeger. 1982. Ein Fall von chronischer pulmonar Hypertonie nach Fenfluramine inname. Wiener Klin. Wschr. 22:618-621.
15. McMurray, J., P. Bloomfield, and H. C. Miller. 1986. Irreversible pulmonary hypertension after treatment with fenfluramine. B.M.J. 292: 239-240.
16. Loogen, F., H. Worth, and G. Schwann. 1985. Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 27:111-124.
17. Pouwels, H. M. M., J. L. R. M. Smeets, E. C. Cheriex, and E. F. M. Wouters. 1990. Pulmonary hypertension and fenfluramine. Eur. Respir. J. 3:606-607.
18. Fotiadis, I., T. Apostolov, A. Koukoulas, N. Michelacakis, and D. Kremastinos. 1991. Fenfluramine-induced irreversible pulmonary hypertension. Postgrad. Med. J. 67:776.
19. Abenhaim, L., Y. Moride, S. Rich, A. Chaslerie, F. Brenot, T. Higgenbottam, C. Oakley, X. Kurz, M. Demedts, E. F. M. Wouters, G. Simonneau, C. A. Wagenvoort, and M. Aubier. 1994. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 105:37S-41S.
20. Hervé, P., L. Drouet, C. Dosquet, J. M. Launay, R. Rain, G. Simonneau, J. Caen, and P. Duroux. 1990. Primary pulmonary hypertension in a patient with familial platelet storage pool disease. Am. J. Med. 89:117-120.
21. McGoon, M. D., and P. M. Vanhoutte. 1984. Aggregatin platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J. Clin. Invest. 74:828-833.
22. Nemecek, G. M., S. R. Coughlin, D. A. Handley, and M. A. Moskowitz. 1986. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. U.S.A. 83:674-678.
23. Sato, K., S. Webb, A. Tucker, M. Rabinovitch, R. F. O'Brien, Y. F. McMurtry, and T. J. Stelzner. 1992. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am. Rev. Respir. Dis. 145:793-797.
24. Eddahibi, S., B. Raffestin, F. Levame, and S. Adnot. 1995. Treatment with 5-hydroxytryptamine potentiates development of pulmonary hypertension in chronically hypoxic rats (abstract). Am. J. Respir. Crit. Care Med. 151(Suppl.):A736.
25. Butt, A. Y., J. Pepke-Zaba, G. Cremona, D. Ravel, and T. Higenbottam. 1995. Effect of dexfenfluramine on isolated human pulmonary arteries (abstract). Am. J. Respir. Crit. Care Med. 151(Suppl.):A735.
26. Martin, F., and F. Artigas. 1992. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J. Neurochem. 59:1138-1144.
27. Eddahibi, S., B. Raffestin, M. Levame, and S. Adnot. 1995. Effect of dexfenfluramine on pulmonary vascular reactivity and development of pulmonary hypertension in chronically hypoxic rats (abstract). Am. J. Respir. Crit. Care Med. 151(Suppl.):A731.
28. Michelakis, E. D., S. L. Archer, J. M. C. Huang, D. P. Nelson, and E. K. Weir. 1995. Anorectic agents inhibit potassium current in pulmonary artery smooth muscle cells (abstract). Am. J. Respir. Crit. Care Med. 151(Suppl.):A725.
29. Weir, E. K., and S. L. Archer. 1995. The mechanisms of acute hypoxic pulmonary vasoconstriciton: the tale of two channels. FASEB J. 9: 183-189.
30. Guy-Grand, B., G. Crefaldi, P. Lefebvre, M. Appelbaum, A. Gries, and P. Turner. 1989. International trial of long-term dexfenfluramine in obesity. Lancet ii:1142-1145.